WoS İndeksli Yayınlar Koleksiyonu

Permanent URI for this collectionhttps://hdl.handle.net/20.500.14627/6

Browse

Filters

2021 - 202518

Settings

Publisher: search.filters.publisher.ElsevierScopus Q: search.filters.scopusQuartile.Q1

Search Results

Now showing 1 - 10 of 18
  • Conference Object
  • Article
    Citation - WoS: 2
    Citation - Scopus: 2
    Novel Triazole-Urea Hybrids as Promising EGFR Inhibitors: Synthesis, Molecular Modeling and Antiproliferative Activity Studies Against Breast Cancer
    (Elsevier, 2025) Ture, Asli; Gulcan, Mehmet Metehan; Birgul, Serap Ipek Dingis; Erdogan, Oguz; Erdogan, Omer; Tuncay, Fulya Oz; Kucukguzel, Ilkay; Öz Tuncay, Fulya; Dingiş Birgül, Serap İpek
    Breast cancer is the second leading cause of mortality among women globally. In this study, novel promising urea derivatives containing a 4-phenyl-5-sulphanylidene-4,5-dihydro-1H-1,2,4-triazole group were synthesized and evaluated for their biological activities against breast cancer. The cytotoxicity and apoptotic profiles of these compounds were assessed on the MCF7 breast cancer cell line and the L929 fibroblast cell line. Compound 5c exhibited the strongest anticancer activity against MCF7 cells with an IC50 value of 56.97+4.22 mu M, while it showed significantly lower cytotoxicity against L929 cells (IC50 = 1651+18.39 mu M). Compound 5c also induced early apoptosis in MCF7 cells, with an apoptosis rate of 18.40% and 5.28%, respectively. Additionally, the EGFR inhibitory activities of the synthesized compounds were evaluated, with compound 5i demonstrating the most potent EGFR inhibition, showing an IC50 value of 35.1 nM. These results suggest that compound 5c likely exerts its anticancer effects through mechanisms other than EGFR inhibition, while compound 5i has significant potential as an effective EGFR inhibitor. Molecular modeling studies were conducted to suggest putative binding interactions of compounds 5d, 5e and 5i with wildtype hEGFR. Further studies are warranted to explore their activity against other cancer types.
  • Conference Object
    Gait Dynamics and Locomotor Function in Familial Mediterranean Fever: A Comparative Study with Healthy Peers
    (Elsevier, 2025) Seker, A. Namli; Albayrak, A.; Yekdaneh, A.; Akgun, O.; Ayaz, N. Aktay
  • Conference Object
  • Conference Object
    Is It Fear or Pain Understanding It's Impact on Physical Performance and Rumination in Children with Rheumatic Diseases
    (Elsevier, 2025) Donmez, I.; Arman, N.; Yekdaneh, A.; Albayrak, A.; Acikgoz, Y.; Ayaz, N. Aktay
  • Conference Object
    Physical Fitness Traffic Lights in Children With Juvenile Idiopathic Arthritis and Familial Mediterranean Fever: A Fitnessgram Roadmap
    (Elsevier, 2025) Albayrak, A.; Arman, N.; Yekdaneh, A.; Donmez, I.; Acikgoz, Y.; Ucar, K.; Ayaz, N. Aktay
  • Conference Object
    Tracking Step Counts in Adolescents with Juvenile Idiopathic Arthritis and Familial Mediterranean Fever: A 3-Month m-Health Monitoring Study Using Smartwatches
    (Elsevier, 2025) Albayrak, A.; Arman, N.; Yekdaneh, A.; Donmez, I.; Acikgoz, Y.; Filiz, G.; Ayaz, N. Aktay
  • Conference Object
  • Article
    Citation - WoS: 5
    Citation - Scopus: 5
    The Effects of Rational Emotive Behavior Therapy and Motivational Interviewing on Emotions, Automatic Thoughts, and Perceived Performance of Elite Female Volleyball Players
    (Elsevier, 2023) Urfa, O.; Asci, F. H.
    Objectives: The aim of this study was to examine the effect of Rational Emotive Behavior Therapy intervention alone (REBT-A) or with motivational interviewing (REBT + MI) on the emotions, automatic thoughts, and perceived performance of elite female volleyball players. Design: and method: Single-case, staggered multiple-baseline AB and ABC designs were adapted in the study. Five female volleyball players participated in the study, of which three players participated in the REBT-A and two players participated in the REBT + MI. The athletes were competing in the national volleyball league (Mage = 28, SD = 5.52). All participants were elite athletes with at least ten years of sports experience. Three scores (T1, T2, T3) were calculated for the athletes' perceived performance, emotion, and automatic thoughts. T1 was the baseline score calculated before the sessions. T2 was calculated after the first two sessions (the first three sessions for REBT + MI) and T3 was calculated after the last three sessions. In the data analysis, percentage changes, effect size, and visual analyzes were used in the T1, T2, and T3 scores. Results: REBT-A and REBT + MI interventions increased perceived performance, positive emotions, and positive automatic thoughts, and decreased negative emotions and negative automatic thoughts. REBT + MI was more advantageous than REBT-A in increasing positive emotion, positive automatic thought, and perceived performance. Conclusions: As a result, REBT alone or with motivational interviewing has a positive effect on perceived performance, emotions, and automatic thoughts, but REBT + MI has greater potential to increase positive constructs.
  • Article
    Citation - WoS: 10
    Citation - Scopus: 10
    Novel Azole-Urea Hybrids as Vegfr-2 Inhibitors: Synthesis,<i> In</I><i> Vitro</I> Antiproliferative Evaluation And<i> In</I><i> Silico</I> Studies
    (Elsevier, 2023) Shirzad, Mohammad Musa; Kulabas, Necla; Erdogan, Omer; Cevik, Ozge; Dere, Damla; Yelekci, Kemal; Kucukguzel, Ilkay
    The vascular endothelial growth factor receptor-2 (VEGFR-2) is a receptor tyrosine kinase known to be abnormally expressed in various malignant tumors, including breast cancer, and is considered one of the most important contributors to tumor angiogenesis. Sorafenib is one of many VEGFR-2 inhibitors that have received approval for clinical use from the US FDA in recent years. Accordingly, in this study, the synthesis of two new pyrazoles, six 1,3,4-oxadiazoles, four 1,3,4-thiadiazoles, and ten 1,2,4-triazole-3-thione derivatives having structural characteristics similar to sorafenib was carried out. A preliminary screening of synthesized compounds and known inhibitors sorafenib and staurosporine at 10 mu M concentration on in vitro activity of VEGFR-2 was performed, and compounds 10c, 8a, and 11 g were identified as the most potent derivatives with% VEGFR-2 residual activities lower than 30%, and dose-dependent inhibition studies was carried out to determine the IC50 values of these inhibitors. Compound 10c was found to be the most potent inhibitor of VEGFR-2 activity with an IC50 value of 0.664 mu M. The anti-proliferative activity of synthesized derivatives was assessed against a breast carcinoma (MCF-7) cell line, a triple negative human breast adenocarcinoma (MDA-MB-231) cell line, and noncancerous fibroblast cells (L929). Compound 8a displayed superior activity when compared to sorafenib against MCF-7 (7.69 fold) and MDA-MB-231 (1.52 fold) cell lines while displaying 3.75-fold less toxicity against the normal L929 cell line. Annexin V binding assay revealed that compound 8a significantly increased early and late apoptosis in MCF-7 cells and late apoptosis and necrosis in MDA-MB-231 cells. Computational studies such as molecular docking and ADMET evaluation were performed to elucidate the binding interactions and druglikeness of the synthesized compounds. The results indicate that compound 8a could be a promising candidate for the development of a novel anti-angiogenic and anti-proliferative agent.